A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 is a phase 1/2 interventional study registered as NCT05761223 by 1ST Biotherapeutics, Inc., with 151 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-06. Interventions recorded: Phase Ia dose-escalation part of FB849 Monotherapy, Phase Ib dose-expansion of FB849 monotherapy, Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab, Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer) and Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer).